AzTrials
AzTrials

Urinary Bladder OveractivePhase 3SYNERGY IINCT02045862

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

A Phase 3 study testing Solifenacin succinate and Mirabegron in people with Urinary Bladder Overactive and Overactive Bladder, run by Astellas Pharma Europe B.V. at 251 sites in 32 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Solifenacin succinate and Mirabegron
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,829 participants
Where
251 sitesin 32 countries
Study dates
17 Mar 2014to 8 Sep 2016
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Main Inclusion at Screening (Visit 1):
  • Subject had completed study 178-CL-101 or study 905-EC-012 (This inclusion criterion would no longer apply once the recruitment for study 178-CL-101 and study 905-EC-012 had been completed. In that case the subject had to have symptoms of "wet" OAB (urinary frequency and urgency with incontinence) for at least 3 months);
  • Subject was willing and able to complete the micturition diary and questionnaires correctly and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings;
  • Main Inclusion at Randomization (Visit 2):
  • Subject had a micturition frequency of on average ≥ 8 times per 24-hour period during the last 7 days of the micturition diary period (incontinence episode should not be counted as a micturition).
  • Subject had experienced at least 3 incontinence episodes during the last 7 days of the micturition diary period.
  • Subject had experienced on average at least 1 urgency episode (grade 3 or 4 on Patient Perception of Intensity of Urgency Scale [PPIUS]) per 24-hour period during the 7-day micturition diary period.

Who cannot join

  • Main Exclusion at Screening (Visit 1):
  • Subject had clinically significant bladder outflow obstruction at risk of urinary retention;
  • Subject had significant PVR volume (> 150 mL);
  • Subject had significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor;
  • Subject has an indwelling catheter or practices intermittent self-catheterization;
  • Subject had evidence of a UTI (urine culture containing > 100,000 cfu/mL), chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs;
Show all 10Show fewer
  • Subject had intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin;
  • Main Exclusion at Randomization (Visit 2):
  • Subject had evidence of a urinary tract infection (UTI) (urine culture containing > 100,000 cfu/mL) as assessed in the Screening visit (V1) samples. The subject could be rescreened after successful treatment of the UTI (confirmed by a dipstick negative for nitrite).
  • Subject had an average total daily urine volume > 3000 mL as recorded in the micturition diary period.

Trial locations and contacts

251 sites in 32 countries.

251 sites in 32 countries

United States75 sites
  • Site US10011

    Albuquerque, New Mexico, 87102

  • Site US10015

    Albuquerque, New Mexico, 87109

  • Site US10037

    Alpharetta, Georgia, 30005

  • Site US10122

    Anaheim, California, 92801

  • Site US10008

    Bala-Cynwyd, Pennsylvania, 19004

  • Site US10110

    Billings, Montana, 59102

  • Site US10282

    Boston, Massachusetts, 02131

  • Site US10060

    Bradenton, Florida, 34208

  • Site US10013

    Burien, Washington, 98166

  • Site US10104

    Chandler, Arizona, 85224

  • Site US10166

    Charleston, South Carolina, 29425

  • Site US10050

    Cleveland, Ohio, 44122

  • Site US10076

    Concord, North Carolina, 28025

  • Site US10065

    Corpus Christi, Texas, 78414

  • Site US10002

    Englewood, New Jersey, 07631

  • Site US10026

    Garden City, New York, 11530

  • Site US10558

    Hanover, Maryland, 21076

  • Site US10082

    Hawaiian Gardens, California, 90716

  • Site US10097

    Hialeah, Florida, 33012

  • Site US10148

    Hialeah, Florida, 33016

  • Site US10153

    Hialeah, Florida, 33016

  • Site US10085

    Houston, Texas, 77058

  • Site US10219

    Houston, Texas, 77094

  • Site US10093

    Houston, Texas, 77099

  • Site US10090

    Hurst, Texas, 76054

  • Site US10091

    Jupiter, Florida, 33458

  • Site US10006

    Kingsport, Tennessee, 37660

  • Site US10040

    Kingston, New York, 12401

  • Site US10088

    Lake Charles, Louisiana, 70601

  • Site US10047

    Lawrenceville, New Jersey, 08648

  • Site US10553

    Lincoln, Nebraska, 68510

  • Site US10132

    Los Angeles, California, 90017

  • Site US10133

    Los Angeles, California, 90036

  • Site US10541

    Medford, Oregon, 97504

  • Site US10154

    Missoula, Montana, 59801

  • Site US10049

    Mobile, Alabama, 36608

  • Site US10112

    Mobile, Alabama, 36608

  • Site US10004

    Mountlake Terrace, Washington, 98043

  • Site US10079

    Mt. Pleasant, South Carolina, 29464

  • Site US10150

    New Port Richey, Florida, 34652

  • Site US10168

    New York, New York, 10065

  • Site US10126

    Newburgh, New York, 12550

  • Site US10109

    Oklahoma City, Oklahoma, 73112

  • Site US10124

    Orlando, Florida, 32803

  • Site US10134

    Orlando, Florida, 32806

  • Site US10149

    Paramount, California, 90723

  • Site US10009

    Pembroke Pines, Florida, 33027

  • Site US10017

    Philadelphia, Pennsylvania, 19114

  • Site US10021

    Phoenix, Arizona, 85051

  • Site US10167

    Pittsburgh, Pennsylvania, 15213

  • Site US10250

    Pittsburgh, Pennsylvania, 15236

  • Site US10248

    Pittsburgh, Pennsylvania, 15243

  • Site US10554

    Plantation, Florida, 33317

  • Site US10028

    Poughkeepsie, New York, 12601

  • Site US10129

    Raleigh, North Carolina, 27609

  • Site US10127

    Roswell, Georgia, 30076

  • Site US10105

    San Antonio, Texas, 78229

  • Site US10111

    San Antonio, Texas, 78229

  • Site US10003

    San Diego, California, 92120

  • Site US10120

    Sandy Springs, Georgia, 30328

  • Site US10155

    Seattle, Washington, 98105

  • Site US10025

    Shreveport, Louisiana, 71106

  • Site US10023

    Simpsonville, South Carolina, 29681

  • Site US10101

    Summerville, South Carolina, 29485

  • Site US10106

    Tarzana, California, 91356

  • Site US10063

    Uniontown, Pennsylvania, 15401

  • Site US10595

    Valley Village, California, 91607

  • Site US10083

    Virginia Beach, Virginia, 23462

  • Site US10067

    Wadsworth, Ohio, 44281

  • Site US10135

    Walla Walla, Washington, 99362

  • Site US10114

    Watertown, Massachusetts, 02472

  • Site US10012

    West Reading, Pennsylvania, 19611

  • Site US10053

    Wheat Ridge, Colorado, 80033

  • Site US10078

    Wichita, Kansas, 67205

  • Site US10062

    Winston-Salem, North Carolina, 27103

Other trials in United States

South Korea20 sites
  • Site KR82014

    Bucheon-si, Gyunggido, 420-767

  • Site KR82006

    Busan, 602-715

  • Site KR82016

    Busan, 602-739

  • Site KR82005

    Daegu, 705-717

  • Site KR82029

    Daegu, 705-718

  • Site KR82019

    Daejeon, 301-721

  • Site KR82023

    Incheon, 405760

  • Site KR82010

    Jeonju, Jeollabuk-do South Korea, 561-712

  • Site KR82012

    Seoul, Gyunggido, 143-729

  • Site KR82003

    Seoul, 05505

  • Site KR82021

    Seoul, 100-380

  • Site KR82020

    Seoul, 110-744

  • Site KR82030

    Seoul, 120-752

  • Site KR82013

    Seoul, 134-701

  • Site KR82017

    Seoul, 134-872

  • Site KR82002

    Seoul, 135-710

  • Site KR82008

    Seoul, 135-720

  • Site KR82015

    Seoul, 136-075

  • Site KR82001

    Seoul, 137-701

  • Site KR82004

    Suwon, Gyeonggi-do, 443-721

Other trials in South Korea

Canada15 sites
  • Site CA15001

    Barrie, Ontario, L4M 7G1

  • Site CA15006

    Brampton, Ontario, L6T 4S5

  • Site CA15003

    Brantford, Ontario, N3S 6T6

  • Site CA15026

    Drummondville, Quebec, J2B 7T1

  • Site CA15035

    Edmonton, Alberta, T5G 0B7

  • Site CA15007

    Kitchener, Ontario, N2N 2B9

  • Site CA15039

    Lévis, Quebec, G6W 5M6

  • Site CA15020

    Montreal, Quebec, H4N 3C5

  • Site CA15040

    Montreal, H2R 1V6

  • Site CA15025

    Québec, Quebec, G1S 2L6

  • Site CA15008

    Saint John, New Brunswick, E2L 3J8

  • Site CA15027

    Sherbrooke, Quebec, J1H 1Z1

  • Site CA15013

    Toronto, Ontario, M4N 3M5

  • Site CA15004

    Toronto, Ontario, M4S 1Y2

  • Site CA15033

    Vancouver, British Columbia, V5Z 4E1

Other trials in Canada

Germany12 sites
  • Site DE49008

    Bad Ems, 56130

  • Site DE49031

    Bergisch Gladbach, Northwest, 51427

  • Site DE49032

    Duisburg, North Rhine-Westphalia, 47179

  • Site DE49002

    Duisburg, 47051

  • Site DE49003

    Eisleben Lutherstadt, Saxony-Anhalt, 06295

  • Site DE49010

    Ganderkesee, 27777

  • Site DE49011

    Halle, 06132

  • Site DE49013

    Leipzig, Saxony, 04105

  • Site DE49034

    Munich, Bavaria, 81377

  • Site DE49001

    Neustadt in Sachsen, 01844

  • Site DE49026

    Rostock, 18107

  • Site DE49014

    Sangerhausen, 06526

Other trials in Germany

Poland12 sites
  • Site PL48018

    Bialystok, 15-351

  • Site PL48013

    Chorzów, 41-500

  • Site PL48014

    Gdynia, 81-384

  • Site PL48004

    Lodz, 90-302

  • Site PL48010

    Lublin, 20-632

  • Site PL48011

    Mysłowice, 41-400

  • Site PL48016

    Opole, 45-086

  • Site PL48005

    Piaseczno, 05-500

  • Site PL48012

    Warsaw, 00-909

  • Site PL48003

    Warsaw, 02-507

  • Site PL48001

    Warsaw, 02-929

  • Site PL48019

    Wroclaw, 50-088

Other trials in Poland

Australia11 sites
  • Site AU61022

    Brisbane, Queensland, 4152

  • Site AU61005

    Broadmeadow, New South Wales, 2292

  • Site AU61015

    Daw Park, South Australia, 5041

  • Site AU61025

    Footscray, Victoria, 3011

  • Site AU61010

    Nambour, Queensland, 4560

  • Site AU61002

    Parkville, Victoria, 3052

  • Site AU61004

    Perth, Western Australia, 6009

  • Site AU61007

    Randwick, New South Wales, 2031

  • Site AU61021

    Randwick, New South Wales, 2031

  • Site AU61019

    Sherwood, Queensland, 4075

  • Site AU61011

    Wollongong, New South Wales, 2522

Other trials in Australia

Czechia11 sites
  • Site CZ42015

    Brno, 602 00

  • Site CZ42003

    Hradec Králové, 500 02

  • Site CZ42001

    Hradec Králové, 50005

  • Site CZ42010

    Olomouc, 772 00

  • Site CZ42014

    Ostrava, 700 30

  • Site CZ42005

    Pilsen, 32600

  • Site CZ42008

    Prague, 12808

  • Site CZ42007

    Prague, 140 00

  • Site CZ42013

    Sternberk, 78501

  • Site CZ42009

    Uherské Hradiště, 686 08

  • Site CZ42006

    Ústí nad Labem, 40001

Other trials in Czechia

Lithuania8 sites
  • Site LT37008

    Kaunas, 47144

  • Site LT37004

    Kaunas, 50009

  • Site LT37011

    Kaunas, LT49449

  • Site LT37012

    Klaipėda, LT-92288

  • Site LT37010

    Vilnius, 10207

  • Site LT37003

    Vilnius, LT-01118

  • Site LT37007

    Vilnius, LT-08661

  • Site LT37009

    Vilnius, LT-09108

Other trials in Lithuania

Slovakia8 sites
  • Site SK42105

    Bratislava, 82101

  • Site SK42107

    Košice, 04001

  • Site SK42101

    Košice, 04013

  • Site SK42103

    Nitra, 949 01

  • Site SK42108

    Poprad, 05801

  • Site SK42104

    Prešov, 080 01

  • Site SK42102

    Trenčín, 91101

  • Site SK42106

    Trenčín, 91101

Other trials in Slovakia

Russia7 sites
  • Site RU70015

    Kazan', 420097

  • Site RU70023

    Penza, 440026

  • Site RU70019

    Saint Petersburg, 194354

  • Site RU70002

    Saint Petersburg, 197089

  • Site RU70022

    Saint Petersburg, 198103

  • Site RU70014

    Saint Petersburg, 199178

  • Site RU70018

    Ufa, 450096

Other trials in Russia

Ukraine7 sites
  • Site UA38002

    Cherenigiv, 14034

  • Site UA38015

    Chernivtsi, 58002

  • Site UA38013

    Dnipro, 49005

  • Site UA38007

    Kiev, 02232

  • Site UA38003

    Kyiv, 02660

  • Site UA38010

    Kyiv, 04053

  • Site UA38008

    Zaporizhzhya, 69600

Other trials in Ukraine

Hungary6 sites
  • Site HU36003

    Csongrád, Csongrád megye, 6640

  • Site HU36007

    Kecskemét, Bacs-Kiskun Megye, 6000

  • Site HU36005

    Pécs, Baranya, 7621

  • Site HU36013

    Sopron, Győr-Moson-Sopron, 9400

  • Site HU36001

    Szentes, Csongrád megye, 6600

  • Site HU36012

    Veszprém, Veszprém megye, 8200

Other trials in Hungary

Romania6 sites
  • Site RO40004

    Bucharest, 042122

  • Site RO40001

    Bucharest, 50659

  • Site RO40005

    Bucharest, 50659

  • Site RO40014

    Cluj-Napoca, Cluj, 400046

  • Site RO40010

    Sibiu, 550245

  • Site RO40002

    Timișoara, 300736

Other trials in Romania

Sweden6 sites
  • Site SE46007

    Borås, 506 30

  • Site SE46005

    Malmö, 211 52

  • Site SE46016

    Stockholm, 111 57

  • Site SE46012

    Stockholm, 141 86

  • Site SE46003

    Stockholm, 182 88

  • Site SE46009

    Uppsala, 753 19

Other trials in Sweden

South Africa5 sites
  • Site ZA27001

    Centurion, Gauteng, 0157

  • Site ZA27006

    Durban, KwaZulu-Natal, 4001

  • Site ZA27013

    Meyerspark, Pretoria, 0184

  • Site ZA27007

    Paarl, Western Cape, 7646

  • Site ZA27002

    Roodepoort, Gauteng, 1709

Other trials in South Africa

Bulgaria4 sites
  • Site BG35908

    Plovdiv, 4003

  • Site BG35902

    Rousse, 7000

  • Site BG35905

    Sofia, 1431

  • Site BG35903

    Sofia, 1606

Other trials in Bulgaria

Italy4 sites
  • Site IT39022

    Ancona, 60126

  • Site IT39007

    Avellino, 83100

  • Site IT39001

    Latina, 04100

  • Site IT39020

    Milan, 20100

Other trials in Italy

Netherlands4 sites
  • Site NL31002

    Amsterdam, 1105 AZ

  • Site NL31006

    Enschede, NL, 7513ER

  • Site NL31005

    Nijmegen, 6532 SZ

  • Site NL31010

    Sneek, 8601 ZK

Other trials in Netherlands

New Zealand4 sites
  • Site NZ64001

    Christchurch, Canterbury, 8013

  • Site NZ64002

    Nelson, 7010

  • Site NZ64003

    Tauranga, 3140

  • Site NZ64006

    Whangarei, 0112

Other trials in New Zealand

Spain4 sites
  • Site ES34004

    Madrid, 28031

  • Site ES34015

    Madrid, 28044

  • Site ES34009

    Madrid, 28046

  • Site ES34002

    Valencia, 46026

Other trials in Spain

Belgium3 sites
  • Site BE32004

    Ghent, 9000

  • Site BE32014

    Roeselare, 8800

  • Site BE32012

    Sint-Truiden, 3800

Other trials in Belgium

Latvia3 sites
  • Site LV37102

    Liepāja, LV-3401

  • Site LV37103

    Olaine, LV-2114

  • Site LV37105

    Riga, LV-1002

Other trials in Latvia

Norway3 sites
  • Site NO47007

    Ålesund, 6003

  • Site NO47006

    Hamar, 2317

  • Site NO47008

    Lierskogen, 3420

Other trials in Norway

United Kingdom3 sites
  • Site GB44006

    Plymouth, PL6 8DH

  • Site GB44001

    Sheffield, South Yorkshire, S10 2JF

  • Site GB44009

    Watford, WD25 7NL

Other trials in United Kingdom

Singapore2 sites
  • Site SG65002

    Singapore, 169608

  • Site SG65003

    Singapore, 229899

Other trials in Singapore

Thailand2 sites
  • Site TH66008

    Bangkok, 10400

  • Site TH66009

    Khon Kaen, 40002

Other trials in Thailand

Denmark1 site
  • Site DK45013

    Aarhus, 8200

Other trials in Denmark

Estonia1 site
  • Site EE37201

    Pärnu, 80010

Other trials in Estonia

Finland1 site
  • Site FI35801

    Kouvola, 45200

Other trials in Finland

Malaysia1 site
  • Site MY60002

    Petaling Jaya, 47500

Other trials in Malaysia

Mexico1 site
  • Site MX52003

    Mexico City, Mexico City, 06700

Other trials in Mexico

Slovenia1 site
  • Site SI38604

    Murska Sobota, 9000

Other trials in Slovenia

About this study

Official title: A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder

The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use.

Being tested
Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
Keywords
Solifenacin Succinate, Mirabegron, Urinary Incontinence, Combination Therapy, Urgency, Nocturia, Overactive Bladder
Medical subject headings
Urinary Bladder, Overactive, Urinary Incontinence, Nocturia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Solifenacin succinateDrug

    Also called Vesicare, Vesitrim, YM905, Vesikur

    Participants received solifenacin 5 mg orally once a day at the same time each day.

  • MirabegronDrug

    Also called Myrbetriq, YM178, Betmiga, Betanis

    Participants received mirabegron 50 mg orally once a day at the same time each day.

  • Placebo to match solifenacinDrug

    Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.

  • Placebo to match mirabegronDrug

    Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.

Study groups in NCT02045862
Study groupRoleWhat they receive
Mirabegron 50 mgActive comparatorParticipants received mirabegron 50 mg once a day for 52 weeks.
Receives: Drug: Mirabegron; Drug: Placebo to match solifenacin
Solifenacin 5 mgActive comparatorParticipants received solifenacin 5 mg once a day for 52 weeks.
Receives: Drug: Solifenacin succinate; Drug: Placebo to match mirabegron
Solifenacin 5 mg + Mirabegron 50 mgExperimentalParticipants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
Receives: Drug: Solifenacin succinate; Drug: Mirabegron

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    A TEAE was defined as an adverse event (AE) observed after taking the first dose of double-blind treatment until 14 days after taking the last dose of double-blind treatment for non-serious AEs and until 30 days after taking the last dose of double-blind treatment for serious adverse events (SAEs). This included abnormal laboratory tests, vital signs or electrocardiogram data that were defined as AEs if the abnormality induced clinical signs or symptoms, required active intervention, interruption or discontinuation of study drug or was clinically significant in the investigator's opinion. The severity of each AE was defined according to the following: Mild (No disruption of normal daily activities); Moderate (Affected normal daily activities) and Severe (Inability to perform daily activities).

    Measured: From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 56 weeks)

  2. Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to the baseline and week 52 clinic visits.

    Measured: Baseline and Week 52

  3. Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours

    A micturition was defined as any voluntary urination (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant in a micturition diary for 7-days before the baseline and week 52 clinic visits.

    Measured: Baseline and Week 52

Secondary outcomes (55)
  1. Change From Baseline to EoT in Mean Volume Voided Per Micturition

    The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period.

    Measured: Baseline and Week 52

  2. Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.

    Measured: Baseline and Week 52

  3. Change From Baseline to EoT in the Patient's Assessment of Treatment Satisfaction-Visual Analogue Scale (TS-VAS)

    The TS-VAS is a visual analogue scale which asks participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.

    Measured: Baseline and Week 52

  4. Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Incontinence Episodes Per 24 Hours

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to the baseline and prior to each visit.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  5. Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The number of incontinence episodes was the total number of times a participant records an incontinence episode during the 7-day micturition diary period prior to each visit.

    Measured: Months 1, 3, 6, 9, 12

  6. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The number of incontinence episodes was the total number of times a participant records an incontinence episode during the 7-day micturition diary period prior to each visit.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  7. Number of Incontinence-Free Days During the 7-Day Micturition Diary Period Prior to Each Visit

    The number of incontinence-free days was the number of valid diary days during the 7-day micturition diary period prior to each visit with no incontinence episodes recorded.

    Measured: Months 1, 3, 6, 9, 12

  8. Number of Incontinence-Free Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit

    The number of incontinence-free days with < 8 micturitions per day was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded and with < 8 micturitions per day.

    Measured: Months 1, 3, 6, 9, 12

  9. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours

    An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The mean number of urgency incontinence episodes was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  10. Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit

    An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceeded by urgency. The number of urgency incontinence episodes was the total number of urgency incontinence episodes recorded by the participant during the 7-day micturition diary period prior to each visit.

    Measured: Months 1, 3, 6, 9, 12

  11. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit

    An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The number of urgency incontinence episodes was the total number of urgency incontinence episodes recorded by the participant during the 7-day micturition diary period prior to each visit.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  12. Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Micturitions Per 24 Hours

    A micturition was defined as any voluntary urination (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant in a micturition diary for 7-days before the baseline and prior to each visit.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  13. Number of Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit (at Months 1, 3, 6, 9, 12 and EoT)

    The number of days with < 8 micturitions was the number of valid diary days during the 7-day micturition diary period with with less than 8 micturitions per day.

    Measured: Months 1, 3, 6, 9, 12

  14. Change From Baseline to EoT in Corrected Micturition Frequency

    Corrected micturition frequency was defined as the mean number of micturitions per 24 hours that participants had at end of treatment if their fluid intake had remained unchanged since baseline. Corrected micturition frequency was calculated as the baseline mean volume voided per micturition multiplied by the baseline mean number of micturitions per 24 hours divided by the mean volume voided per micturition at EoT.

    Measured: Baseline and Month 12

  15. Change From Baseline to Months 3, 6 and 12 in Mean Volume Voided Per Micturition

    The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period prior to each visit.

    Measured: Baseline and Months 3, 6, 12

  16. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours

    Urgency was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. An urgency episode was defined as any micturition or incontinence episode recorded by the participant in the micturition diary for 7 days prior to each visit as 3 or 4 on the Patient Perception of Intensity of Urgency Scale (PPIUS), where 0 = No urgency; 1 = Mild urgency; 2 = Moderate urgency, could delay voiding a short while; 3 = Severe urgency, could not delay voiding; 4 = Urge incontinence, leaked before arriving to the toilet.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  17. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours

    A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the participant gets up in the morning with the intention to stay awake). The mean number of nocturia episodes was calculated from data recorded by the participant in the micturition diary for 7 days prior to each visit."

    Measured: Baseline and Months 1, 3, 6, 9, 12

  18. Number of Nocturia Episodes Reported During the 7-Day Micturition Diary Period Prior to Each Visit

    A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the participant gets up in the morning with the intention to stay awake). The number of nocturia episodes was the number of times a participant recorded a nocturia episode during the 7-day micturition diary period prior to each visit.

    Measured: Months 1, 3, 6, 9, 12

  19. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Nocturia Episodes During the 7-Day Micturition Diary Period Prior to Each Visit

    A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the participant gets up in the morning with the intention to stay awake). The number of nocturia episodes was the number of times a participant recorded a nocturia episode during the 7-day micturition diary period prior to each visit

    Measured: Baseline and Months 1, 3, 6, 9, 12

  20. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Pads Used Per 24 Hours

    The mean number of pads used per 24 hours was calculated from data recorded by the participant in the micturition diary for 7 days prior to each visit.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  21. Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit

    The number of pads used was the number of times a participant recorded a new pad used during the 7-day micturition diary period prior to each visit.

    Measured: Months 1, 3, 6, 9, 12

  22. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit

    The number of pads used was the number of times a participant recorded a new pad used during the 7-day micturition diary period prior to each visit.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  23. Change From Baseline to Months 1, 3, 6, 9 and 12 in the OAB-q Symptom Bother Score

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  24. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Health-Related Quality of Life Questionnaire (HRQoL): Total Score

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  25. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Coping

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. HRQoL subscales (coping, concern, sleep and social) and total score were transformed to range from 0 (worst quality of life) to 100 (best quality of life), with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  26. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Concern

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. HRQoL subscales (coping, concern, sleep and social) and total score were transformed to range from 0 (worst quality of life) to 100 (best quality of life), with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  27. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Sleep

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consisted of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each time was scored 1-6. HRQoL subscales (coping, concern, sleep and social) and total score were transformed to range from 0 (worst quality of life) to 100 (best quality of life), with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  28. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQL Subscale Score: Social

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. HRQoL subscales (coping, concern, sleep and social) and total score were transformed to range from 0 (worst quality of life) to 100 (best quality of life), with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  29. Change From Baseline to Months 1, 3, 6, 9 and 12 in the Patient's Assessment of TS-VAS

    The TS-VAS is a visual analogue scale which asks participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  30. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Patient Perception of Bladder Condition (PPBC)

    The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  31. Percentage of Participants in Each Category of Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Month 12 and EoT

    The PGIC is a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).

    Measured: Month 12

  32. Percentage of Participants in Each Category of PGIC Scale: Impression in General Health at Month 12 and EoT

    The PGIC is a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).

    Measured: Month 12

  33. Number of Participants With Change From Baseline to EoT in European Quality of Llife in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility

    The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).

    Measured: Baseline and 12 Months

  34. Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-care

    The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).

    Measured: Baseline and Month 12

  35. Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities

    The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).

    Measured: Baseline and Month 12

  36. Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort

    The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and had 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).

    Measured: Baseline and Month 12

  37. Number of Participants With Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression

    The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and had 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).

    Measured: Baseline and Month 12

  38. Change From Baseline to Months 6, 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed

    The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.

    Measured: Baseline and Months 6,12

  39. Change From Baseline to Months 6, 12 and EoT in WPAI:SHP Score: Percent Impairment While Working

    The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.

    Measured: Baseline and Months 6, 12

  40. Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Overall Work Impairment

    The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes arre expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.

    Measured: Baseline and Months 6, 12

  41. Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Activity Impairment

    The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.

    Measured: Baseline and Months 6, 12

  42. Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Months 1, 3, 6, 9, 12 and EoT

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The percentage of participants with no incontinence episodes recorded during the last 3 days of the 7-day micturition diary is reported.

    Measured: Months 1, 3, 6, 9, 12

  43. Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Months 1, 3, 6, 9, 12 and EoT

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  44. Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQoL Total Score at Months 1, 3, 6, 9, 12 and EoT

    The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  45. Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Months 1, 3, 6, 9, 12 and EoT

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  46. Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Months 1, 3, 6, 9, 12 and EoT

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The percentage of participants with no incontinence episodes recorded during the 7-day micturition diary is reported.

    Measured: Months 1, 3, 6, 9, 12

  47. Percentage of Participants With Micturition Frequency Normalization at Months 1, 3, 6, 9, 12 and EoT

    The percentage of participants with micturition frequency normalization was defined as participants who had ≥ 8 micturitions/24 hours at baseline and < 8 micturitions/24 hours postbaseline at months 1, 3, 6, 9, 12 and EoT.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  48. Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Months 1, 3, 6, 9, 12 and EoT

    The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  49. Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Months 1, 3, 6, 9, 12 and EoT

    The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  50. Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Months 1, 3, 6, 9, 12 and EoT

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The symptom bother portion consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  51. Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Months 1, 3, 6, 9, 12 and EoT

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The OAB-q is a self-reported questionnaire with items relating to symptom bother and HRQoL. The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  52. Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  53. Percentage of Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q Symptom Bother Scale and ≥1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT

    The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The symptom bother portion of the OAB-q consists of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  54. Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q HRQL Total Score and ≥ 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT

    The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant in a micturition diary for 7 days prior to each visit. The HRQoL portion of the OAB-q consists of 25 HRQoL items comprising 4 HRQoL subscales, each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.

    Measured: Baseline and Months 1, 3, 6, 9, 12

  55. Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Postvoid Residual (PVR) Volume

    PVR volume was assessed by ultrasonography or a bladder scanner.

    Measured: Baseline and Months 1, 3, 6, 9, 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2014 (estimated)
  2. Study start17 Mar 2014
  3. Primary completion8 Sep 2016
  4. Study completion8 Sep 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
1,829 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02045862
Sponsor's protocol ID
178-CL-102
Other IDs
2012-005736-29
Acronym
SYNERGY II
Status last verified
Oct 2024
First submitted
23 Jan 2014
Last updated
31 Oct 2024
Data monitoring committee
No
Individual data sharing
Yes: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Publications

  • Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1.

    PubMed 29866467

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Solifenacin succinate and Mirabegron in people with Urinary Bladder Overactive and Overactive Bladder, run by Astellas Pharma Europe B.V. at 251 sites in 32 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 251 sites in United States, South Korea, Canada, Germany, Poland and 27 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Jun 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (time frame: From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 56 weeks)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02045862, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in